Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khurram Wadud

Endocrinology, Diabetes & Metabolism Jacksonville, FL Medical Doctor

NPI 1801877576 CMS profile 263172

915 W Monroe St Ste 200, Jacksonville, FL 32204

Open in the dashboard

General payments

$76,937

1,096 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$261,005 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Khurram Wadud of Jacksonville, FL is reported in the CMS Open Payments database as having received $76,937 across 1,096 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $261,005 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,143 139
2024 General $2,938 150
2023 General $3,598 170
2022 General $19,039 200
2021 General $16,642 127
2020 General $12,081 88
2019 General $19,498 222

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khurram Wadud
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Khurram Wadud were reported at $3,143. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Khurram Wadud Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $19,498 $494 $123–$2,253 $163
2020 $12,081 $335 $85–$1,841 $114
2021 $16,642 $398 $88–$1,981 $132
2022 $19,039 $364 $88–$1,568 $149
2023 $3,598 $420 $113–$1,614 $160
2024 $2,938 $440 $121–$1,646 $164
2025 $3,143 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $28,605 41 payments
  2. AstraZeneca Pharmaceuticals LP $27,290 64 payments
  3. Novo Nordisk Inc $4,174 184 payments
  4. Abbott Laboratories $1,960 124 payments
  5. Sanofi-Aventis U.S. LLC $1,394 68 payments
  6. Insulet Corporation $1,336 63 payments
  7. Lilly USA, LLC $1,288 69 payments
  8. Medtronic MiniMed, Inc. $1,169 16 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $966 55 payments
  10. Dexcom, Inc. $932 42 payments
  11. Other $7,823 370 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,415 26 payments
  2. Food and Beverage $19,932 1,052 payments
  3. Consulting Fee $2,040 2 payments
  4. Travel and Lodging $1,497 12 payments
  5. Education $53 4 payments
Products named General payments · program years 2019–2025
  1. Kerendia $28,605 41 payments
  2. FARXIGA $27,280 63 payments
  3. RYBELSUS $3,258 95 payments
  4. Ozempic $1,362 119 payments
  5. Minimed 670G System $1,169 16 payments
  6. Omnipod $1,018 42 payments
  7. FreeStyle Libre 3 $881 56 payments
  8. Dexcom G6 Transmitter $818 35 payments
  9. Tresiba $802 70 payments
  10. UNITHROID $715 40 payments
  11. Other $15,040 811 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

5,365

Median for Endocrinology: 1,959

Drug cost

$3,573,506

Median for Endocrinology: $890,201

Branded share of claims

69.5%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 606 $1,089,242
Mounjaro Tirzepatide Brand 209 $364,598
Jardiance Empagliflozin Brand 189 $248,857
Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt Brand 162 $248,088
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 145 $185,593
Farxiga Dapagliflozin Propanediol Brand 141 $151,561
Tresiba Flextouch U-200 Insulin Degludec Brand 105 $126,087
Rybelsus Semaglutide Brand 71 $122,198
Trulicity Dulaglutide Brand 49 $81,951
Januvia Sitagliptin Phosphate Brand 64 $80,360

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$221,547

Medicare's payments for the services billed

Medicare patients

987

Average age 73

Services billed

5,077

605 women, 382 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 53%
Ischemic heart disease 45%
Chronic kidney disease 40%
COPD 26%
Depression 26%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$342 189 —
TEPEZZA
$195 — —
MOUNJARO
$160 209 —
Korlym
$131 — —
UNITHROID
$98 251 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,096 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record